## Answer
(model generated chain of thought explanation)

The key to answering this question is to understand the potential effects of each option on fetal development, particularly in relation to the findings described.

A. Betamethasone: This corticosteroid is used to accelerate fetal lung maturation and reduce the risk of respiratory distress syndrome (RDS) in preterm infants. However, it does not directly affect the development of the cardiovascular system or the presence of a positive Babinski sign.

B. Folic acid: Folic acid supplementation is recommended for all pregnant women at high risk of neural tube defects (NTDs), including those with a history of previous NTDs. Given that this infant was born to a G1P1 mother, it's likely that the mother had a previous history of NTDs, which increases her risk of having another child with a similar condition. Folic acid supplementation would have prevented or significantly reduced the risk of NTDs in this infant.

C. Indomethasone: This nonsteroidal anti-inflammatory drug (NSAID) is used to reduce the risk of RDS in preterm infants by inhibiting prostaglandin synthesis, which is necessary for fetal lung maturation. However, it does not directly affect the development of the cardiovascular system or the presence of a positive Babinski sign.

D. Prostaglandins: These hormones are involved in labor and can stimulate uterine contractions. While they may be used to induce labor or augment delivery, their use is generally reserved for specific situations where there's a need to expedite delivery. In this case, the continuous murmur on cardiac exam suggests that the infant may have had a patent ductus arteriosus (PDA), which could be related to the positive Babinski sign and the presence of cyanosis.

Given the information provided, the most likely factor that would have prevented the abnormal finding in this infant is folic acid supplementation due to its potential to prevent NTDs, which are directly related to the cardiovascular system's development.